… In multiple myeloma (MM), the interplay between malignant plasma cells and their micro-…
to the understanding of the role of the immunomodulatory drug (IMiD) class. IMiDs are a group …

Background: Multiple myeloma (MM) is a hematological … with the incorporation of
immunomodulatory drugs (IMiDs) and … -diagnosed multiple myeloma, relapsed refractory myeloma …

… multiple myeloma was quite poor in the last century, but it has significantly improved with the
incorporation of novel agents, immunomodulatory drugs (… and immunomodulatory activities, …

… Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell
malignancy, have dramatically improved. The development of the immunomodulatory drugs (…

Multiple Myeloma (MM) is an incurable malignancy with current treatment choices primarily
comprising combination regimens implemented with a risk-adapted approach. Cereblon (…

… The introduction of new agents immunomodulatory drugs (IMiDs) and … multiple myeloma
(MM). Thalidomide was the first immunomodulatory agent approved for use in myeloma. …

Although immunomodulatory drugs (IMiDs), such as thalidomide, lenalidomide, and
pomalidomide, are widely used in the treatment of multiple myeloma (MM), the molecular …

… of immunomodulatory drugs into the treatment protocol, the outcome of multiple myeloma …
% of patients surviving for 10 years thus shifting multiple myeloma to a treatable condition. …

… Immunomodulatory drugs (IMiDs) and proteasome inhibitors have dramatically changed
management of multiple myeloma (MM). While MM remains incurable, consolidation and …

… Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in
patients with relapsed multiple myeloma. Blood 2002;100:3063–3067.17 Copyright American …